Effects of cellular adoptive immunotherapy in combination with immune checkpoint inhibition and TLR-agonists in soft tissue sarcoma mouse models
Year: 2026
Type: dissertation
Abstract: Soft tissue sarcomas are a heterogeneous group of malignancies deriving from mesenchymal tissues. If unresectable, life expectancy quickly deteriorates to a poor MOS rate of less than 12 months under anthracycline-based standard chemotherapy treatment. Since the approval of doxorubicin in 1974, no significant improvement has been achieved in the treatment of inoperable soft tissue sarcomas, so there is an urgent need to find better alternatives (Italiano 2020). Subject of my research is to evaluate the effectiveness of an innovative adoptive Immunotherapy combination against undifferentiated pleomorphic sarcomas in cell cultures as well as in heterotopic and orthotopic mouse models. The ACT that consists of a mix of Cytokine-Induced Killer cells, Cytotoxic T Lymphocytes, Lymphokine Activated Killer cells and gammadelta-T cells was combined with aPD-1 antibodies and TLR-3, -7 and -9 agonists (Triple therapy). Particular emphasis was placed on induced changes in the TME to understand the mechanisms that could contribute to the antitumor efficacy of the therapy. Killing assays confirmed the preassumption that the killing efficacy against sarcoma cells in vitro was enhanced by the combination of all four ACT effector cell types compared to single cell type ACT. Subcutaneous undifferentiated pleomorphic sarcoma mouse models showed notably enhanced overall survival rates when treated with the combination ACT compared to untreated mice (20,6 d MOS [ACTmono] vs 16,0 d MOS [Vehicle]). This beneficial effect was even improved by additional treatment with aPD-1 and the TLR agonist mix (25,4 d MOS [Triple]). The Triple therapy regimen showed striking response rates with complete responses in 50 % of the specimens on day 14 of the treatment. In orthotopic undifferentiated pleomorphic sarcoma mouse models, similarly beneficial antitumor effects in immunotherapeutically treated mice could be observed. Analyzing the TME, FACS data revealed enhanced T cell and B cell infiltration and activation in sarcomas responsive to ACTmono or Triple therapy compared to progressive tumors. Moreover, an enhanced generalized APC activation shows the potent stimulation of the murine immune system. Summarizing, the implemented ACT antitumor effects do not rely only on direct cytotoxic properties but also lead to potent interactions between the innate and the adaptive immune system that synergistically combat the undifferentiated pleomorphic sarcomas in living models. As most of the induced beneficial changes within the TME vanish after days to weeks and the tumors start to regrow, it is crucial to understand the tumor escape mechanisms. Therefore, more detailed analysis of the TME has to be undertaken to potentially find ways to prevent sarcoma cells from overcoming the great antitumor immune response that is induced by the immunotherapy combinations.
Author: Bochtler, Jonathan
Institution: University of Cologne
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: soft tissue sarcoma, malignant fibrous histiocytoma, adoptive cellular immunotherapy, immune checkpoint blockade, anti-PD-1, TLR agonists, TLR9 agonist, cytokine-induced killer cells, cytotoxic T lymphocytes, lymphokine-activated killer cells, γδ T cells, tumor microenvironment, tumor-infiltrating lymphocytes, antitumor immunity, orthotopic mouse model
Open Access status: green
OpenAlex ID: W7152935653
